• Colorectal Cancer Info MAIN MENU
  • Screening & Prevention MAIN MENU
  • Patient & Family Support MAIN MENU
  • Get Involved MAIN MENU
  • Funding Research MAIN MENU
  • Our Mission MAIN MENU

Subscribe to the Newsletter

Exciting news in the colon cancer world! Last week, the experimental drug MGD007 was cleared by the FDA for Phase I clinical trials in colon cancer, scheduled to start later this year. MGD007 is different from other drugs currently available because it kills cancer cells in a different way. Specifically, it binds to a protein on immune system cells (or T-cells) and directs them to kill cells that express a protein found on 95% of primary and metastatic colon cancer cells.

This means MGD007 has the potential to be highly effective in shrinking colon and rectal tumors in much more targeted way and with a lower dosage, so it’s less toxic. Until this point, the drug has been effective on cell lines and in animals; we’re thrilled to see the results on this upcoming Phase I human clinical trial. This data was presented to thousands of medical professionals, researchers and advocates at the 2014 American Association of Cancer Research (AACR) meeting. For more details, take a look at the full release.

Interested in learning more about clinical trials and how you can participate? Check out our Clinical Trials Matching Service.

Don’t forget, the Colon Cancer Alliance serves as a source of information about colon health. If you have questions or are in need of support, please contact our free Helpline at (877) 422-2030. We’re here to help.

Categories:

Related reading